Nina Chavez, MBA, FACMPE: Biosimilars and Patient Out-of-Pocket Costs
Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd, discusses the role that biosimilars have to play in reducing patients’ out-of-pocket costs in cancer care.
Transcript
You know, anything that can decrease the cost to the patient is the best thing for the patient.
We have financial counselors, we have a lot of copay cards, we have a lot of drug assistance, drug replacement. We as a practice work very hard to get therapies to the patients that they cannot afford. And so, if there's a way that these biosimilars coming into the market can not only lower the total cost of care, but they can lower the patients’ out-of-pocket and that stress and anxiety that the patient has, I think that's fantastic.
I don't know how it will play out because it's so new, and right now, like I said, they're kind of marketing like the brand; they're not that much cheaper. They don't want to disrupt [average selling price, ASP]; it's more about, “we’ll give you a contract to use all of our stuff, including our biosimilar, instead of using this other guy’s, right?”
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
